Two U.S. states have filed a lawsuit against a major cord blood banking company, alleging the firm misled expectant parents about the medical benefits of storing their newborn's umbilical cord blood stem cells, according to a report from MedicalXpress published in March 2026. The states contend that the company made exaggerated or unsubstantiated claims regarding the therapeutic potential of stored cord blood, potentially influencing parents to pay significant storage fees under false pretenses. Cord blood banking, which involves collecting and preserving stem cells from a newborn's umbilical cord at birth, is a service that has been marketed as a form of biological insurance against future diseases. However, the scientific consensus, based largely on observational data and limited randomized controlled trial evidence, suggests that the likelihood of a child ever using their own stored cord blood is quite low — estimated at less than 0.04% by some analyses. Major medical organizations, including the American Academy of Pediatrics, have historically recommended against private cord blood banking for most families absent a specific diagnosed medical need. The lawsuit represents an escalating regulatory and legal scrutiny of direct-to-consumer health marketing practices in the stem cell industry. Details regarding the specific states involved, the identity of the defendant company, the exact claims at issue, and the damages sought were not fully disclosed in the available source material. VITALIS notes that the evidentiary basis of the legal claims has not yet been adjudicated, and the company's response to the allegations is not yet known. Source: https://medicalxpress.com/news/2026-03-states-sue-cord-blood-company.html